In little over a month, Oxford BioDynamics have inked two deals relating to the distribution and sales of its market leading Prostate Cancer PSE test. Does this mark the start of a turnaround for the company?

Veteran, 'company turn-around' specialist Iain Ross recently joined Oxford BioDynamics as Chairman.  His mandate, to take a leading 3D Genomics company with a commercial-ready portfolio into the mainstream market-place via industry deals and partnerships.   "I've never in-herited a portfolio like this", Chairman, Iain Ross. 

Often market dynamics alone can see a share bounce back and return multiples but Fusion Antibodies (FAB) has a few more catalysts than that, as I explain in my latest blog !